The Mismatch Between Disease and Treatment Structure
HS is not a skin infection that happens to recur. It is not an episodic rash with identifiable external triggers. It is a chronic, systemic, inflammatory condition in which skin lesions are the visible expression of internal processes — gut dysfunction, hormonal dysregulation, immune irregularity, and metabolic imbalance — that operate continuously rather than episodically, regardless of whether a lesion is actively present.
The dominant treatment structure applied to HS in routine clinical practice is episodic and symptom-targeted. Antibiotics are prescribed for active infection and inflammation. Steroids are injected into acute lesions to reduce swelling. Abscesses are drained when they reach the point of requiring drainage. This treatment structure is designed for acute, self-limiting conditions — conditions where the episode is the disease, and addressing the episode resolves the problem. Applied to HS, this structure consistently produces the same outcome: temporary resolution of the current episode, followed by recurrence, because the internal processes generating episodes have not been addressed.
The mismatch is structural, not incidental. It is not that antibiotics are being incorrectly prescribed or that steroid injections are being misapplied. It is that the entire logic of episodic, symptom-targeted treatment is incompatible with the biology of a condition that is driven by continuous internal dysfunction rather than discrete external events.
"HS is not a skin problem. It is a systemic inflammatory condition expressing through the skin."
What Quick Fixes Actually Do
Understanding precisely what episodic interventions achieve — and what they leave unaddressed — is essential for understanding why serious care requires something different.
Antibiotics in HS
Antibiotics in HS work by reducing the bacterial component of the inflammatory response in active lesions. HS lesions are not primarily infectious — they begin as sterile inflammatory events driven by follicular occlusion — but bacterial colonisation of ruptured follicles and abscesses amplifies and sustains the inflammatory cascade. Antibiotics reduce this bacterial amplification, which produces measurable reduction in acute lesion activity and some reduction in inflammatory markers.
What antibiotics do not address is the follicular occlusion that initiates lesion formation, the hormonal environment that influences follicular biology, the gut dysfunction that sustains systemic inflammation, or the immune dysregulation that produces disproportionate inflammatory responses to follicular disruption. These drivers continue operating during and after antibiotic treatment, which is why lesions return when antibiotics are stopped — or, in many long-standing cases, continue to form even while antibiotics are being taken, as the internal environment remains unchanged.
Extended antibiotic use in HS produces an additional complication: progressive disruption of the gut microbiome, which itself becomes an independent source of systemic inflammatory drive and immune dysregulation. The gut disruption produced by long-term antibiotic use partially explains the pattern of diminishing returns that many patients experience — each course becomes less effective than the previous one, not because of antibiotic resistance alone, but because the gut environment that was sustaining immune regulation is progressively impaired.
Steroid Injections
Intralesional steroid injections reduce acute inflammatory activity in individual lesions with considerable short-term effectiveness. For a painful, acutely inflamed nodule, a steroid injection can produce rapid reduction in pain and swelling, and in some cases accelerates resolution of the individual lesion. This represents genuine symptomatic benefit.
The limitation is precisely circumscribed: the injection addresses the inflammatory state of that specific lesion, in that specific location, at that specific time. It has no effect on the internal environment that generated the lesion — the hormonal state, the gut-derived inflammatory load, the immune activation pattern. That environment continues operating after the injection, producing new lesions, often in adjacent areas, sometimes within days or weeks of the injection that resolved the previous one. Repeated steroid injections over months and years also carry cumulative effects on the local tissue environment that can alter the character of disease in treated areas.
Incision and Drainage
Drainage of fluctuant abscesses provides immediate relief of pressure and pain, which is clinically warranted when an abscess has reached the point of requiring drainage. It does not, however, alter disease course. The abscess that was drained healed from a lesion that formed because of ongoing internal dysfunction — and that dysfunction continues to generate new lesions after the drained lesion has resolved. Repeated drainage of HS abscesses without addressing the internal environment is management of individual lesion consequences, not treatment of the disease producing them.
Ayurvedic classical texts distinguish between Shaman Chikitsa — pacification treatment targeting symptomatic relief — and Shodhana Chikitsa — purification treatment addressing the underlying accumulation of imbalance. In HS, most conventional management operates at the Shaman level: reducing the immediate manifestation without addressing the Ama, Dosha imbalance, and Srotorodha (channel blockage) that are generating it. Serious Ayurvedic care for HS is Shodhana-oriented: it targets the internal accumulations that are sustaining disease. Shaman approaches are not wrong — they have a place in managing acute discomfort — but they cannot substitute for Shodhana in a condition whose drivers are systemic and deeply established.
What Serious Care Actually Requires
Serious care for HS is characterised by three structural features that distinguish it from episodic intervention: continuity, system-level targeting, and phased progression.
Continuity
A chronic disease driven by continuous internal dysfunction requires continuous treatment — not treatment that starts when a lesion appears and stops when it resolves. The internal processes generating HS activity do not pause between visible episodes. Gut dysfunction is operating between flares. Hormonal dysregulation continues during remission periods. Immune irregularity persists at sub-clinical levels even when the skin is quiet. Treatment that is only active when lesions are visible is addressing a fraction of the timeline during which the disease is operating.
Serious care maintains continuous correction of the internal environment throughout the treatment period — not management of individual episodes as they appear. This requires a different patient relationship with treatment: not reaching for an intervention when a lesion develops, but maintaining a structured approach to the internal drivers that would generate lesions if left uncorrected.
System-Level Targeting
Because HS is driven by multiple interacting internal systems — gut, hormonal, immune, metabolic — serious care must address each of these systems, not just the inflammatory output they collectively produce. Addressing gut dysfunction alone, without correcting the hormonal environment, leaves one major driver intact. Addressing inflammation without restoring gut health leaves the primary source of inflammatory drive uncorrected. The multi-system nature of HS requires treatment that operates across all relevant systems simultaneously, in a sequence that reflects how they interact rather than treating each in isolation.
This is structurally different from the single-target approach of most episodic management, where each intervention addresses one aspect of one episode. System-level targeting requires a broader therapeutic architecture that can engage multiple drivers in a coordinated way — which is precisely what a phase-based protocol is designed to provide.
Phased Progression
Serious care for HS is not a single sustained intervention — it is a progression through phases, each building on the previous, each addressing a different level of the internal dysfunction. Reducing inflammatory load must precede tissue healing, because healing cannot consolidate in a persistently inflamed environment. Hormonal correction must accompany gut restoration, because the hormonal environment influences gut function and vice versa. Recurrence prevention requires the systemic resilience that only develops after the primary drivers have been substantially corrected.
Quick-fix approaches have no phases — they are each a discrete, complete intervention. Serious care has a trajectory: an arc from active disease through stabilisation to prevention that spans months, with each phase having specific clinical objectives and specific markers of progress.
"When a condition keeps recurring, it usually follows an underlying pattern that needs to be understood and addressed — not suppressed."
The Time Investment — Why It Cannot Be Compressed
The most common objection to serious care for HS is the time it requires. Patients who have been managing with episodic interventions are accustomed to treatment timelines measured in days or weeks — antibiotic courses, steroid injections, drainage procedures. Serious, phase-based care operates on timelines measured in months to years. This is not a commercial choice or an arbitrary extension of the treatment relationship; it is determined by the biology of what is being corrected.
Gut microbiome restoration from a significantly disrupted baseline takes months, not days. Hormonal rebalancing in patients with established androgen excess or insulin resistance proceeds gradually, constrained by the pace at which endocrine systems can rebalance. Immune regulatory function, depleted by years of chronic activation, rebuilds over extended periods. Tissue healing in areas with significant fibrotic change requires sustained anti-inflammatory correction before meaningful structural improvement occurs. None of these processes can be accelerated beyond their biological pace by increasing the intensity of treatment — they are constrained by physiology, not by dosing.
The time investment in serious care is proportional to the duration and severity of disease at the point treatment begins. Patients who begin structured care at earlier stages of HS require shorter timelines because the degree of systemic correction needed is less extensive. Patients with long-standing, systemically embedded disease require longer timelines because the internal environment that needs to be corrected is more deeply disrupted. Both require more time than any episodic intervention — and the investment of that time produces something that episodic intervention cannot: correction of the internal environment that generates the disease, rather than management of its output.
What Serious Care Produces That Quick Fixes Cannot
The clinical outcome of serious, phase-based, system-level care for HS is qualitatively different from the outcome of episodic management — not just quantitatively better. Episodic management, even when executed well, produces a managed chronic disease: ongoing episodes at variable frequency, ongoing interventions, ongoing dependency on external control of an internal problem that has not been corrected. This is not a failure of episodic management on its own terms — it is exactly what episodic management is designed to produce.
Serious care, when it succeeds, produces a changed internal environment: one in which the drivers of HS activity have been substantially corrected, and in which the condition — while it may never be completely absent — operates at a fundamentally reduced level without continuous external management. The difference between a patient who has been managed episodically for five years and one who has undergone eighteen months of serious systemic correction is not a difference in symptom severity at any given moment — it is a difference in the internal state that determines whether those symptoms will keep returning.
This is what patients who have tried everything and found that nothing works have not yet accessed: not a better version of what they have already tried, but a structurally different approach to a condition that requires something different from what episodic intervention can offer.